The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

#### Notice of Exempt Offering of Securities

# OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number	) Previous Names	None	Entity Type
<u>0001402479</u>		Marine Operations, Inc.	X Corporation
Name of Issuer	Marvin's Pla	-	Limited Partnership
Atlas Therapeutics Corp		,	Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organizat	ion		Business Trust
NEVADA			Other (Specify)
Year of Incorporation/	Organization		
Over Five Years Ago			
X Within Last Five Years (Speci	fy Year) 2007		
Yet to Be Formed			
2. Principal Place of Business and	Contact Information		
Name of Iss	suer		
Atlas Therapeutics Corp			
Street Addr	ess 1	Stre	et Address 2
4640 ADMIRALTY WAY, SUIT	E 500		
City St	tate/Province/Country	ZIP/PostalCode	Phone Number of Issuer
MARINA DEL REY CA	LIFORNIA	90292	310-496-5727
3. Related Persons			
Last Name	Firs	t Name	Middle Name
Bernstein	J.B.		
Street Address 1	Street	Address 2	
4640 Admiralty Way, Suite 500			
City	State/Prov	vince/Country	ZIP/PostalCode
Marina del Rey	CALIFORNIA	9029	2
<b>Relationship:</b> X Executive Offic	er X Director X Promo	ter	
Clarification of Response (if Nece	essary):		
Last Name	Firs	t Name	Middle Name
Colker, MD, FACN	Carlon		
Street Address 1	Street	Address 2	
4640 Admiralty Way, Suite 500			
City	State/Prov	vince/Country	ZIP/PostalCode
Marina del Rey	CALIFORNIA	9029	2
<b>Relationship:</b> X Executive Offic	er Director Promote	er	

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Hariri	Robert	J.
<b>Street Address 1</b> 4640 Admiralty Way, Suite 500	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Marina del Rey	CALIFORNIA	90292
<b>Relationship:</b> Executive Officer <i>Y</i>	K Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Diamandis	Peter	
Street Address 1	Street Address 2	
4640 Admiralty Way, Suite 500 <b>City</b>	State/Province/Country	ZIP/PostalCode
Marina del Rey	CALIFORNIA	90292
<b>Relationship:</b> Executive Officer <i>X</i>	K Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Aronne	Louis	
<b>Street Address 1</b> 4640 Admiralty Way, Suite 500	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Marina del Rey	CALIFORNIA	90292
<b>Relationship:</b> Executive Officer <i>Y</i>	K Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Levy Street Address 1	Peter Street Address 2	
4640 Admiralty Way, Suite 500	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Marina del Rey	CALIFORNIA	90292
<b>Relationship:</b> X Executive Officer	Director Promoter	
Clarification of Response (if Necessa	ary):	
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing	Pharmaceuticals	Telecommunications
Investment Banking Pooled Investment Fund		
Is the issuer registered as	X Other Health Care	Other Technology Travel
an investment company under	Manufacturing Real Estate	
the Investment Company	Commercial	Airlines & Airports
Act of 1940?	Construction	Lodging & Conventions
Yes No		Tourism & Travel Services
Other Banking & Financial Ser	vices REITS & Finance	Other Travel

Business ServicesResidentialOtherEnergyOther Real EstateCoal MiningElectric UtilitiesElectric UtilitiesImage: ConservationEnergy ConservationImage: ConservationImage: ConservationEnvironmental ServicesImage: ConservationImage: ConservationOil & GasImage: ConservationImage: Conservation5. Issuer SizeImage: ConservationImage: Conservation

<b>Revenue Range</b>	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
X \$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)				
	Section 3(c)(1)	Section 3(c)(9)		
	Section 3(c)(2)	Section 3(c)(10)		
	Section 3(c)(3)	Section 3(c)(11)		
	Section 3(c)(4)	Section 3(c)(12)		
	Section 3(c)(5)	Section 3(c)(13)		
	Section 3(c)(6)	Section 3(c)(14)		
	Section 3(c)(7)			

### 7. Type of Filing

X New Notice Date of First Sale 2012-02-10 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

# X Equity

Debt

Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as Yes X No a merger, acquisition or exchange offer? Clarification of Response (if Necessary): 11. Minimum Investment Minimum investment accepted from any outside investor \$0 USD 12. Sales Compensation Recipient Recipient CRD Number X None (Associated) Broker or Dealer CRD Number X None (Associated) Broker or Dealer X None Street Address 1 Street Address 2 City State/Province/Country **ZIP/Postal** Code State(s) of Solicitation (select all that apply) All States Foreign/non-US Check "All States" or check individual States 13. Offering and Sales Amounts **Total Offering Amount** \$1,500,000 USD or Indefinite **Total Amount Sold** \$725,000 USD Total Remaining to be Sold \$775,000 USD or Indefinite Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$397,300 USD Estimate

Clarification of Response (if Necessary):

Amount includes: i) \$364,000 to Dr. Colker to repay outstanding debt; and ii) \$33,300 to Mr. Bernstein for compensation.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Atlas Therapeutics Corp	/s/ J.B. Bernstein	J.B. Bernstein	Chief Executive Officer	2012-02-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.